Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas

Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators

(2010) Montserrat Ayala-Ramirez et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Pulmonary metastases in children with osteosarcoma: characteristics and impact on patient survival

(2010) Darshana D. Rasalkar et al.   PEDIATRIC RADIOLOGY

Survival of Patients with Metastatic Malignant Pheochromocytoma and Efficacy of Combined Cyclophosphamide, Vincristine, and Dacarbazine Chemotherapy

(2009) Kaoru Nomura et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine

(2008) Hui Huang et al.   CANCER

Use of the Tyrosine Kinase Inhibitor Sunitinib in a Patient with von Hippel-Lindau Disease: Targeting Angiogenic Factors in Pheochromocytoma and Other von Hippel-Lindau Disease-Related Tumors

(2008) Camilo Jimenez et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Analysis of Survival by Tumor Response and Other Comparisons of Time-to-Event by Outcome Variables

(2008) James R. Anderson et al.   JOURNAL OF CLINICAL ONCOLOGY

Patient With Malignant Paraganglioma Responding to the Multikinase Inhibitor Sunitinib Malate

(2008) Noah M. Hahn et al.   JOURNAL OF CLINICAL ONCOLOGY